Q4 2025 · 13F-HR
Sanofi (SNY, SNYNF)holdings as filed
Filed 2026-02-11 · accession 0001193125-26-045633
$310.4M
Reported value
8
Positions
2025-12-31
Period end
The Brief · Sanofi (SNY, SNYNF) · Q4 2025
AI · grounded in 13F
Sanofi SNY established a new position in MapLight Therapeutics Inc. MPLT valued at $16.02M. The fund closed its position in Omada Health Inc. OMDA, reducing its holdings by $11.61M. It also exited its position in LAVA Therapeutics N.V. 4PKB for $2.99M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G59665102 | MGTX | MeiraGTx Holdings plc | $97.0M | 31.2% | 12,197,737 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences, Inc. | $91.5M | 29.5% | 1,157,926 | Common | SOLE |
| 670002401 | NVAX | Novavax | $46.2M | 14.9% | 6,880,481 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio | $39.8M | 12.8% | 821,917 | Common | SOLE |
| 45254E107 | IMRX | Immuneering Corp | $17.8M | 5.74% | 2,708,559 | Common | SOLE |
| 56565P103 | MPLT | MapLight Therapeutics Inc. | $16.0M | 5.16% | 912,041 | Common | SOLE |
| 28617K101 | ELDN | Eledon | $1.2M | 0.40% | 814,980 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $810,356 | 0.26% | 244,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.